A Prescription Drug User Fee Act target date of December 12, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License Application ...
Lower targets proven: The Ez-PAVE trial showed that targeting LDL below 55 mg/dL cut major cardiovascular events by 33% compared to the 70 mg/dL goal. Earlier prevention focus: New U.S. guidelines ...
Ez-PAVE delivers the first direct trial evidence that targeting LDL below 55 mg/dL is superior to below 70 mg/dL in ASCVD ...
BOSTON -- A PCSK9 inhibitor contributed extra LDL cholesterol lowering as an early add-on to standard high-intensity statins in the acute period of ST-segment elevation MI (STEMI), the small ...
New late-breaking clinical trial data presented at ACC and published simultaneously in JACC show benefit of investigational medicine AZD0780 on top of standard of care WILMINGTON, Del.--(BUSINESS WIRE ...
You might have high LDL cholesterol and not even know it. We spoke to experts about how to monitor this health stat so you ...
Nat Clin Pract Cardiovasc Med. 2006;3(6):290-291. A positive causal relationship between the concentration of LDL cholesterol and the future risk of cardiovascular events is one of the best-proven ...
Please provide your email address to receive an email when new articles are posted on . Spatz, an associate professor of cardiology and epidemiology at Yale University School of Medicine, discussed ...
Use of OTC dietary supplements is increasingly common, sometimes replacing guideline-recommended therapies. Rosuvastatin was associated with larger reductions in LDL-C compared with placebo, fish oil, ...
Add Yahoo as a preferred source to see more of our stories on Google. https://www.tipranks.com/news/the-fly/apellis-price-target-lowered-to-18-from-20-at-wedbush ...
Lower may indeed be better, suggests a new analysis of the FOURIER trial addressing outcomes in patients whose LDL cholesterol was brought below 40 mg/dL. The findings, say investigators, support some ...
The ability of niacin to influence LDL-P is under active investigation and it appears that the beneficial effects of niacin extend beyond the traditional evaluation of the 'lipid profile.' Taken ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results